1. Medtech Insight
  2. >>Policy & Regulation

Exec Chat: Medtronic Diabetes VP Talks Value-Based Health Care

 
• By David Filmore

Medtronic Diabetes exec Suzanne Winter talks with Medtech Insight about her business' approach to value-based health care, including recently inked agreements with insurers such as Aetna and United Healthcare.

Value dial

It's news to virtually no one in the device industry that value-based health care is the foundation on which medtech companies must now approach hospitals, providers, payers and patients with their offerings. New market strategies that emphasize outcomes and cost-savings, and total solutions rather than widgets, are taking on increasing importance.

But what's happening on the ground? One place to look is in the diabetes device sector, where the connection between...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

Dxcover Launches US Operations With New Headquarters In Tennessee

 
• By Natasha Barrow

Dxcover sets up new Clinical Laboratory Improvement Amendments (CLIA) lab in Franklin, Tennessee.

EnsoData Boosts AI Sleep Tech With $20M Series B Funding, Targets Underdiagnosis Crisis

 
• By Shubham Singh

EnsoData positions itself as device-agnostic and interoperable, with FDA-cleared software that can integrate with all major devices. CEO Mortara said this flexibility helps maximize patient reach by enabling both direct provider engagement and integration with device manufacturers.

FDA Blocks Some Olympus Endoscopes From Entering US

 
• By Brian Bossetta

After multiple warning letters and safety communications, the US FDA has decided to block the import of certain endoscopes from Olympus. In total, the agency’s action pertains to 58 device models manufactured by the Japanese firm used in urinary, respiratory, abdominal and pelvic procedures.